ClearPoint Neuro, Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 30, 2020. The company develops and commercializes MRI-guided systems and products for minimally invasive procedures, principally its ClearPoint brain-surgery platform. Results are unaudited.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Total revenue | $3.52 million | $2.93 million | $9.11 million | $8.01 million |
| Operating loss | $1.27 million | $0.91 million | $3.95 million | $3.18 million |
| Net loss | $1.48 million | $1.12 million | $5.20 million | $3.89 million |
| Net loss per share | $0.09 | $0.08 | $0.33 | $0.31 |
| Gross margin | 80% | 66% | 75% | 64% |
- Q3 product revenue declined 10% to $2.33 million, while service and other revenue rose 256% to $1.19 million. For the first nine months, product revenue fell 13% to $6.03 million and service and other revenue increased 193% to $3.08 million.
- At September 30, cash and cash equivalents were $14.67 million, versus $5.70 million at year-end 2019. Current assets were $20.14 million and current liabilities $3.71 million.
- Operating cash use was $5.40 million for the nine months, compared with $2.38 million in 2019. Investing activities used $0.44 million; financing activities provided $14.82 million.
- Debt included $17.5 million principal of five-year, floating-rate secured convertible notes issued in January 2020, plus an $896,000 Paycheck Protection Program loan. The company repaid approximately $2.8 million principal and accrued interest on its prior secured notes. Convertible notes are secured by company assets and convertible at $6 per share, subject to adjustments.
- Total liabilities were $21.70 million and stockholders’ equity was $149,000. The company reported an accumulated deficit of approximately $117.9 million.
Material changes versus comparable periods
- Nine-month revenue increased 14%, but net loss widened 34%; operating expenses rose across research and development, sales and marketing, and general and administrative categories.
- Biologics and drug-delivery revenue increased substantially, primarily from clinical-service retainers and additional partner relationships. This offset lower functional neurosurgery product and capital equipment revenue.
- Gross margin improved as higher-margin service revenue made up a larger share of sales. Management cautioned that margins could decline if revenue mix and overhead allocations return toward historical patterns.
- ClearPoint system use declined to 200 cases in Q3 (231 a year earlier) and 507 cases for nine months (600 a year earlier). Active Surgical Centers increased to more than 60 from more than 50; biologics and drug-delivery partners rose to approximately 25 from 20.
Outlook, commentary and risks
- Management said cash and cash equivalents, together with financing proceeds and the PPP loan, were sufficient to fund operations and meet obligations for at least the next 12 months. This is management’s assessment, not a financial forecast; the company has no reported profitability.
- No specific revenue or earnings guidance was provided. The company did not expect meaningful therapy-product revenue in 2020 and targeted a limited market release in 2021. It expected initial steps toward European ClearPoint sales and clinical advisory services in late 2020 and 2021.
- COVID-19 disrupted elective procedures, which historically represented about 80% of ClearPoint procedures, and delayed clinical trials and hospital capital purchases. Management said the duration and financial impact remained uncertain; renewed restrictions could further affect procedures, revenue, cash flow and hospital spending.
- The company applied for forgiveness of its $896,000 PPP loan, but forgiveness was not assured. It also identified risks involving access to future financing, suppliers with limited alternatives, market adoption, regulation, competition and product development.
- Revenue concentration warrants attention: one customer represented 15% of Q3 revenue and 18% of nine-month revenue. Approximately $7.9 million of bank balances exceeded FDIC-insured limits. No legal proceedings were reported.
Important facts for investors to verify
- Whether elective procedures and ClearPoint case volumes recover, and how that translates into product revenue.
- Whether biologics and drug-delivery service revenue is recurring and supported by active trials, given pandemic-related delays and customer concentration.
- Cash burn relative to management’s stated 12-month liquidity assessment, and the company’s ability to fund operations beyond that period.
- Convertible-note terms, interest burden, security and potential dilution; also the outcome of the PPP loan-forgiveness application.
- Whether improved gross margins persist as revenue mix changes, and whether planned therapy and European commercialization milestones are achieved.